How current research is addressing optimization of the use of ctDNA for improving outcomes in metastatic colorectal cancer – Andrea Sartore Bianchi
In the evolving molecular treatment landscape of metastatic colorectal cancer, the identification of druggable alterations
is pivotal to achieve the best therapeutic opportunity for each patient. Because the number of actionable targets is expanding, there is the need to timely detect their presence or emergence to guide the choice of different available treatment options.
Liquid biopsy, through the analysis of circulating tumor DNA (ctDNA), has proven safe and effective as a complementary method to address cancer evolution while overcoming the limitations of tissue biopsy.
Check out our review just published in Clinical Cancer Research highlighting unmet needs and how current research is addressing optimization of the use of ctDNA for improving outcomes in metastatic colorectal cancer: https://lnkd.in/defTtdwB
Source: Andrea Sartore Bianchi/Linkedin
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023